FDA Approves Expanded Use of Lilly's Forteo [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis
July 23, 2009
First and only FDA-approved anabolic agent in the U.S. now indicated
to treat the leading type of secondary osteoporosis INDIANAPOLIS, July
23 /PRNewswire-FirstCall/ -- Today, Eli Lilly and Company announced
that the U.S. Food and Drug Administration (FDA) has approved a new
use for its osteoporosis drug Forteo [teriparatide (rDNA origin)
injection] to treat osteoporosis associated with sustained, systemic
glucocorticoid therapy in men and women at high risk of fracture.
First and only FDA-approved anabolic agent in the U.S. now indicated
to treat the leading type of secondary osteoporosis INDIANAPOLIS, July
23 /PRNewswire-FirstCall/ -- Today, Eli Lilly and Company announced
that the U.S. Food and Drug Administration (FDA) has approved a new
use for its osteoporosis drug Forteo [teriparatide (rDNA origin)
injection] to treat osteoporosis associated with sustained, systemic
glucocorticoid therapy in men and women at high risk of fracture.
Comentarios
Publicar un comentario